Fatty liver breakthrough? scientists target gene switches
NCT ID NCT06332677
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at how certain gene regulators, called SUV420H1/2, affect fatty liver disease (NAFLD). Researchers will analyze data from 260 people and use lab models to see if blocking these genes could reduce liver fat and damage. The goal is to find a new way to treat this common liver condition.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this research could point toward a new treatment for fatty liver disease by targeting specific genes.
- What could go wrong
- This is an early-stage observational and lab study, not a clinical treatment trial. Results may not lead to a usable therapy for years, if at all.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 260 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2023
- Expected to finish
-
Apr 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: We will analyse data and samples from subjects with the following criteria: * Subjects aged\>18; * Subjects who have already given their consent to genetic analysis and whose samples and data have already been collected as part of the SERENA, REASON and MAFALDA studies; * Subjects who have given their consent to participate in this study. In particular, subjects with the following characteristics were included respectively: * in the SERENA study: 1. Diagnosis of NAFLD 2. Age between 45 and 75 years old 3. Any of the following criteria: 1. F3-F4 fibrosis, determined histologically, or by non-invasive techniques, or evidence of cirrhosis deriving from biochemical tests or imaging methods; 2. Family history of related first-degree primary liver cancer, or carrier status of rare mutations associated with the development of HCC (such as mutations in APOB and TERT) 3. Male patient with type 2 diabetes or obesity carrying at least three genetic variants in PNPLA3, TM6SF2, MBOAT7. * in the REASON study: Patients aged\>18, who have given their consent to participate in the study, who underwent the fol- lowing procedures: * liver biopsy for suspected non-alcoholic steatohepatitis (NASH) at the time of diagnosis; * liver resection for hepatocarcinoma, other liver lesions (including secondaries from other neo- plasms and benign focal lesions, which will allow obtaining healthy starting liver tissue), biopsies of whole liver explants obtained at the time of liver transplantation AND cholecystectomies. * In the MAFALDA study: Patients undergoing bariatric surgery for grade 3 obesity (BMI ≥40 Kg/m2) or grade 2 obesity plus: * metabolic comorbidities (uncontrolled hypertension, diabetes, dyslipidemia); * lack of contraindication to surgery (e.g. advanced liver disease with portal hypertension); * willingness to sign an informed consent. Exclusion Criteria: * Individuals not reporting one of the inclusion criteria listed above or reporting at-risk alcohol intake (\>30/20 g/day in M/F), viral and autoimmune hepatitis or other causes of liver disease will be ex- cluded.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NAFLD are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico - Istituto di Ricovero e Cura a Carattere Scientifico di natura pubblica
RECRUITINGMilan, 20122, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can talk therapy and mindfulness shrink a fatty liver?
- A smartphone app may help curb the silent march of fatty liver disease toward cirrhosis
- AI and blood biomarkers could catch hidden liver damage
- A protein supplement may fight fatty liver in teens
- Can a single pill tackle both fatty liver and diabetes?
- A new MRI technique could see inside the Liver's metabolism without a biopsy